284 related articles for article (PubMed ID: 14601136)
1. Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice.
Harding CO; Neff M; Jones K; Wild K; Wolff JA
J Gene Med; 2003 Nov; 5(11):984-93. PubMed ID: 14601136
[TBL] [Abstract][Full Text] [Related]
2. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin.
Christensen R; Alhonen L; Wahlfors J; Jakobsen M; Jensen TG
Exp Dermatol; 2005 Jul; 14(7):535-42. PubMed ID: 15946242
[TBL] [Abstract][Full Text] [Related]
3. Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle.
Harding CO; Wild K; Chang D; Messing A; Wolff JA
Gene Ther; 1998 May; 5(5):677-83. PubMed ID: 9797873
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation in the pathophysiology of hyperphenylalaninemia in the PAH(enu2) mouse model of phenylketonuria.
Dobrowolski SF; Lyons-Weiler J; Spridik K; Vockley J; Skvorak K; Biery A
Mol Genet Metab; 2016 Sep; 119(1-2):1-7. PubMed ID: 26822703
[TBL] [Abstract][Full Text] [Related]
5. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).
Hamman KJ; Winn SR; Harding CO
Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493
[TBL] [Abstract][Full Text] [Related]
6. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.
Ding Z; Harding CO; Rebuffat A; Elzaouk L; Wolff JA; Thöny B
Mol Ther; 2008 Apr; 16(4):673-81. PubMed ID: 18362925
[TBL] [Abstract][Full Text] [Related]
7. Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy.
Chen L; Thung SN; Woo SL
Mol Ther; 2007 Jun; 15(6):1079-85. PubMed ID: 17406346
[TBL] [Abstract][Full Text] [Related]
8. A bone mineralization defect in the Pah
Dobrowolski SF; Tourkova IL; Robinson LJ; Secunda C; Spridik K; Blair HC
Mol Genet Metab; 2018 Nov; 125(3):193-199. PubMed ID: 30201326
[TBL] [Abstract][Full Text] [Related]
9. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: implications for tetrahydrobiopterin-responsive hyperphenylalaninemia.
Thöny B; Ding Z; Martínez A
FEBS Lett; 2004 Nov; 577(3):507-11. PubMed ID: 15556637
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of BH4 -responsive hyperphenylalaninemia--as it occurs in the ENU1/2 genetic mouse model.
Sarkissian CN; Ying M; Scherer T; Thöny B; Martinez A
Hum Mutat; 2012 Oct; 33(10):1464-73. PubMed ID: 22644647
[TBL] [Abstract][Full Text] [Related]
12. Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.
Winn SR; Scherer T; Thöny B; Ying M; Martinez A; Weber S; Raber J; Harding CO
Mol Genet Metab; 2018 Jan; 123(1):6-20. PubMed ID: 29331172
[TBL] [Abstract][Full Text] [Related]
13. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
Winn SR; Scherer T; Thöny B; Harding CO
Mol Genet Metab; 2016 Jan; 117(1):5-11. PubMed ID: 26653793
[TBL] [Abstract][Full Text] [Related]
14. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
[TBL] [Abstract][Full Text] [Related]
15. Quantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry.
Heintz C; Troxler H; Martinez A; Thöny B; Blau N
Mol Genet Metab; 2012 Apr; 105(4):559-65. PubMed ID: 22300847
[TBL] [Abstract][Full Text] [Related]
16. New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
Lagler FB; Gersting SW; Zsifkovits C; Steinbacher A; Eichinger A; Danecka MK; Staudigl M; Fingerhut R; Glossmann H; Muntau AC
Biochem Pharmacol; 2010 Nov; 80(10):1563-71. PubMed ID: 20705059
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cell energy deficit and oxidative stress contribute to osteopenia in the Pah
Dobrowolski SF; Sudano C; Phua YL; Tourkova IL; Spridik K; Goetzman ES; Vockley J; Blair HC
Mol Genet Metab; 2021 Mar; 132(3):173-179. PubMed ID: 33602601
[TBL] [Abstract][Full Text] [Related]
18. Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria.
Hamman K; Clark H; Montini E; Al-Dhalimy M; Grompe M; Finegold M; Harding CO
Mol Ther; 2005 Aug; 12(2):337-44. PubMed ID: 16043102
[TBL] [Abstract][Full Text] [Related]
19. The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria.
Harding CO; Neff M; Wild K; Jones K; Elzaouk L; Thöny B; Milstien S
Mol Genet Metab; 2004 Jan; 81(1):52-7. PubMed ID: 14728991
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice.
Scherer T; Allegri G; Sarkissian CN; Ying M; Grisch-Chan HM; Rassi A; Winn SR; Harding CO; Martinez A; Thöny B
J Inherit Metab Dis; 2018 Jul; 41(4):709-718. PubMed ID: 29520738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
